Score Overview
Explore the 2021 public Archive ranking →
Where ACADIA Pharmaceuticals Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- ACAD
2009: 83.9% · 2021: 51.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 20.22 | — |
1 Year2025-09-29 | $ 21.32 | -5.16% |
5 Years2021-09-29 | $ 16.96 | 19.22% |
10 Years2016-09-29 | $ 32.70 | -38.17% |
20 Years2006-09-29 | $ 8.64 | 134.03% |
All Time2004-05-27 | $ 6.70 | 201.79% |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | 20 Years2006-09-29 | All Time2004-05-27 |
|---|---|---|---|---|---|---|
| Price | $ 20.22 | $ 21.32 | $ 16.96 | $ 32.70 | $ 8.64 | $ 6.70 |
| Return | — | -5.16% | 19.22% | -38.17% | 134.03% | 201.79% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1.13B | $ 380M | $ 956M |
| 2025 | $ 1.07B | $ 391M | $ 819M |
| 2024 | $ 957M | $ 226M | $ 755M |
| 2023 | $ 726M | -$ 61M | $ 438M |
| 2022 | $ 517M | -$ 215M | $ 416M |
| 2021 | $ 484M | -$ 167M | $ 520M |
| 2020 | $ 441M | -$ 281M | $ 631M |
| 2019 | $ 339M | -$ 235M | $ 697M |
| 2018 | $ 223M | -$ 245M | $ 473M |
| 2017 | $ 124M | -$ 289M | $ 341M |
| 2016 | $ 17M | -$ 271M | $ 529M |
| 2015 | -$ 164M | $ 215M | |
| 2014 | $ 120K | -$ 92M | $ 322M |
| 2013 | $ 1M | -$ 37M | $ 185M |
| 2012 | $ 4M | -$ 20M | $ 107M |
| 2011 | $ 2M | -$ 22M | $ 31M |
| 2010 | $ 42M | $ 15M | $ 37M |
| 2009 | $ 6M | -$ 45M | $ 47M |
| 2008 | $ 1M | -$ 64M | $ 60M |
| 2007 | $ 7M | -$ 56M | $ 126M |
| 2006 | $ 8M | -$ 45M | $ 83M |
| 2005 | $ 10M | -$ 34M | $ 43M |
| IPO2004 | $ 4M | -$ 25M | $ 35M |
ACADIA Pharmaceuticals Inc fundamental performance
Between 2020 and 2025, revenue grew from $ 441M to $ 1.07B and net income went from -$ 281M to $ 391M. Revenue increased in every one of those 5 years; net income in 3.
Between 2015 and 2025, net income went from -$ 164M to $ 391M. Revenue increased in every one of those 10 years; net income in 6.
ACADIA Pharmaceuticals Inc currently holds a 20-year HDB Score of 4.8 out of 10. How the HDB Score is calculated.
Membership
Continue ACAD’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
